New Jersey: Glenmark Pharmaceuticals Inc., USA (Glenmark) has announced to launch1 of Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial). Glenmark’s Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial) is bioequivalent and therapeutically equivalent to the reference listed drug, Mycamine®2 for Injection, 50 mg/vial and 100 mg/vial, of Astellas Pharma US, Inc. NDA – 021506 and the company will begin distribution in September 2025.
According to IQVIA® sales data for the 12-month period ending June 2025, the Mycamine® for Injection, 50 mg/vial and 100 mg/vial market3 achieved annual sales of approximately $60.7 million*.
Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, “We are excited to announce the launch of Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial), growing our portfolio of products within the institutional channel, while also strengthening our commitment to bring quality and affordable alternatives to market for patients in need.”
Glenmark’s Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial) is only approved
for the indication(s) listed in Glenmark’s approved label.
